FIELD: medicine.
SUBSTANCE: invention relates to medicine and aims at treating castration-resistant prostate cancer. Simultaneously with a combination of preparations of cabazitaxel 25 mg/m2 body surface once in 3 weeks + prednisolone 10 mg daily, amber acid is prescribed in the form of oral administration twice day for 50–200 mg after meals with duration of the therapeutic course for 3 weeks.
EFFECT: method enables reducing the number of side effects of chemotherapy.
1 cl
Title | Year | Author | Number |
---|---|---|---|
METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2694259C2 |
METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2700573C2 |
METHOD OF TREATING CASTRATION-RESISTANT PROSTATE CANCER | 2017 |
|
RU2673816C1 |
METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2696287C2 |
METHOD OF CASTRATION-RESISTANT PROSTATE CANCER TREATMENT | 2017 |
|
RU2696288C2 |
METHOD OF TREATING PATIENTS WITH METASTASES IN LYMPH NODES AND OLIGOMETASTATIC DISEASE IN BONES OF SKELETON IN PROSTATE CANCER | 2018 |
|
RU2695348C2 |
METHOD FOR COMPLEX HORMONE-CHEMORADIATION TREATMENT OF LOCALIZED OR LOCALLY ADVANCED PROSTATE CANCER OF HIGH AND VERY HIGH RISK OF PROGRESSING | 2019 |
|
RU2716942C2 |
MEANS OF TREATMENT AND RELAPSE PREVENTION OF PROSTATE CANCER | 2006 |
|
RU2325160C1 |
AGENT FOR NAUSEA AND VOMITING PROPHYLAXIS AND ARRESTING | 2000 |
|
RU2197961C2 |
USE OF PARP INHIBITOR IN TREATMENT OF CHEMOTHERAPY-RESISTANT OVARIAN CANCER OR BREAST CANCER | 2018 |
|
RU2777519C2 |
Authors
Dates
2019-07-12—Published
2017-10-16—Filed